

# Cardiorespiratory Fitness Is Related to Physical Inactivity, Metabolic Risk Factors, and Atherosclerotic Burden in Glucose-Intolerant Renal Transplant Recipients

Kirsten Armstrong,\* Dhruvo Rakhit,<sup>†</sup> Leanne Jeffriess,<sup>†</sup> David Johnson,\* Rodel Leano,<sup>†</sup> John Prins,<sup>‡</sup> Luke Garske,<sup>§</sup> Thomas Marwick,<sup>†</sup> and Nicole Isbel\*

Departments of \*Nephrology, <sup>†</sup>Endocrinology, and <sup>§</sup>Respiratory Medicine and <sup>‡</sup>School of Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia

The mechanisms of reduced cardiorespiratory fitness (CF) in renal transplant recipients (RTR) have not been studied closely. This study evaluated the relationships between CF and specific cardiovascular risk factors (metabolic syndrome [MS], physical inactivity, myocardial ischemia, and atherosclerotic burden) in glucose-intolerant RTR. Data were recorded on 71 glucose-intolerant RTR (mean age 55 yr; 55% male; median transplant duration 5.7 yr). MS was defined using National Cholesterol Education Programme Adult Treatment Panel III criteria. Resting and exercise stress echocardiography were performed, and myocardial ischemia was identified by new or worsening wall motion abnormalities. Cardiorespiratory fitness was determined using peak oxygen uptake ( $\text{VO}_2$ ) by expired gas analysis. Atherosclerotic burden was assessed by carotid intima-media thickness (IMT). Mean peak  $\text{VO}_2$  was  $19 \pm 7$  ml/kg per min and was significantly lower than predicted peak  $\text{VO}_2$  ( $29 \pm 6$  ml/kg per min;  $P < 0.001$ ). Patients with MS (63%) had reduced CF ( $17 \pm 6$  versus  $22 \pm 8$  ml/kg per min;  $P = 0.001$ ) and were more likely to be physically inactive (76 versus 48%;  $P = 0.02$ ). CF was reduced in 14 patients with myocardial ischemia ( $15 \pm 3$  versus  $20 \pm 7$  ml/kg per min;  $P = 0.05$ ). CF was positively correlated with male gender, height, and physical activity and inversely correlated with number of MS risk factors and IMT (adjusted  $R^2 = 0.66$ ). Carotid IMT added incremental value to clinical variables in determining  $\text{VO}_2$  (adjusted  $R^2 = 0.65$  versus  $0.63$ ;  $P = 0.04$ ). Reduced CF is associated with physical inactivity, MS, and atherosclerotic burden in glucose-intolerant RTR. Further studies should address whether increasing exercise and modifying MS risk factors improve CF in RTR.

*Clin J Am Soc Nephrol* 1: 1275–1283, 2006. doi: 10.2215/CJN.00210106

Cardiorespiratory fitness (CF) is a well-validated predictor of cardiovascular outcome both in individuals with underlying cardiovascular disease (CVD) and in normal individuals (1). Patients with advanced chronic kidney disease have reduced CF, attributable to the uremic state and deconditioning imposed by chronic illness (2,3). Although CF improves after transplantation (4), it remains reduced compared with age- and gender-matched control subjects (5).

In the general population, the correlates of CF may be divided broadly into four categories: (1) Demographic variables; (2) cardiovascular risk factors such as glucose intolerance, hypertension, obesity, and dyslipidemia (6–8), which commonly coexist as the metabolic syndrome (MS); (3) behavioral factors including smoking and physical inactivity (9); and (4) myocardial parameters such as left ventricular (LV) hypertrophy and systolic dysfunction (6). Similar variables may limit CF in renal transplant recipients (RTR). MS risk factors, such as glucose

intolerance, itself an extremely common complication of renal transplantation (10) that contributes significantly to the cardiovascular risk factor profile of this patient group (11), are particularly important because they occur frequently in RTR (12). However, other factors that are relevant to renal transplantation, such as immunosuppression, renal dysfunction, and subclinical atherosclerosis, also may determine CF in RTR (13,14). To date, no studies have explored specifically the correlates of reduced CF in RTR. In particular, the relationship among MS risk factors, physical activity, and CF in RTR is uncertain. We evaluated the relationships between CF and specific cardiovascular risk factors (MS, physical inactivity, myocardial ischemia, and atherosclerotic burden) in a high-risk (glucose-intolerant) cohort of established (>1 yr) RTR.

## Materials and Methods

### Study Design and Population

This study was an observational analysis of glucose-intolerant RTR from the Princess Alexandra Hospital (Brisbane, Australia). Inclusion criteria were patients who were >1 yr after transplant and had impaired glucose tolerance or diabetes defined according to 1999 World Health Organization specifications (15) and an estimated GFR (eGFR) >25 ml/min using the Nankivell formula (16). All eligible patients gave informed consent to participate in the study, which was approved by the Human Ethics Committee of the University of Queensland and

Received January 17, 2006. Accepted August 20, 2006.

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).

**Address correspondence to:** Dr. Kirsten Anne Armstrong, c/o Department of Renal Medicine, Level 2, ARTS Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane Qld 4102, Australia. Phone: +61-7-3240-5080; Fax: +61-7-3240-5480; E-mail: [kirsty@ascom.net](mailto:kirsty@ascom.net)

Princess Alexandra Hospital. A group ( $n = 25$ ) of individuals who had normal glucose tolerance and were age, gender, and transplant duration matched were used as a control cohort.

### Clinical Data

Demographic data were recorded, including age, gender, race, cause of renal disease, and duration of current transplant. Assessment of cardiovascular risk factors included a history of any of the following either before or after transplantation: (1) A previous cardiac event (nonfatal myocardial infarction, acute coronary syndrome requiring hospitalization, coronary artery bypass graft, or percutaneous coronary intervention), (2) peripheral vascular disease (angioplasty, bypass, or amputation), (3) cerebrovascular disease (transient ischemic attack or stroke with neurologic deficit), (4) hypertension (previous or current use of antihypertensive agents or self-reported), (5) dyslipidemia (previous or current use of lipid-lowering therapy or self-reported), (6) diabetes (defined as previous or current use of oral hypoglycemic agents or insulin or self-reported), and (7) smoking status (current, former, or never). MS was defined according to the National Cholesterol Education Panel Adult Treatment Panel III (NCEP) criteria (17).

### Physical Activity Assessment

Physical activity data were recorded using a core set of questions, adapted from the Physical Activity Statewide Questionnaire (18) (Table 1). The number of sessions and the total time spent on each category of activity in the preceding week were noted, as well as the patients' perceptions of how active they considered themselves to have been (activity status). From the patients' responses, it was determined whether they were achieving recommended targets of physical activity (activity target) (19).

### Clinical Measurements

BP, weight, height, and waist and hip circumference were measured using standardized equipment, and body mass index (BMI) and waist-to-hip ratio were determined. Central obesity was defined as waist circumference  $\geq 102$  cm in men or  $\geq 88$  cm in women (20).

### Biochemical Analyses

After an 8-h overnight fast, serum concentrations of creatinine, hemoglobin, glucose, HbA1c%, calcium, phosphate, C-reactive protein, homocysteine, and lipids (total cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol, and triglycerides) were analyzed using standard techniques.

### CF

CF was assessed by measuring oxygen consumption ( $\text{VO}_2$ ) by breath-by-breath analysis of expired gas (V29C Sensorimedics, Yorba Linda, CA), during standard treadmill exercise testing. The  $\text{VO}_2$  at the time of termination of the test was recorded as peak  $\text{VO}_2$ . Age-predicted peak  $\text{VO}_2$  and ventilatory limitation (%) were determined using standardized formulas (21,22). The respiratory quotient, defined as the ratio of  $\text{CO}_2$  production to  $\text{VO}_2$ , was calculated and a value  $>1$  at peak exercise was taken as a physiologic indicator of maximal effort. Mean peak  $\text{VO}_2$  in the study cohort was compared with mean peak  $\text{VO}_2$  in the control cohort.

### Two-Dimensional and Exercise Echocardiography

Before and immediately after exercise, patients had resting two-dimensional echocardiography. Images were obtained in five standard views of the left ventricle and were saved onto magneto-optical disc for off-line analysis.

### Atherosclerotic Burden

Acquisition of carotid intima-media thickness (IMT) data was performed before exercise testing using high-resolution B-mode ultrasonography (ATL HDI5000, Philips/ATL, Bothell, WA) with a 12-MHz imaging probe and automated off-line analysis. Our method for IMT measurement was described previously (23).

### Echocardiographic Analysis

A physician who was blinded to the clinical data interpreted the echocardiographic data. Left atrial and LV volumes were measured from standard views. Ejection fraction was computed by Simpson's method of discs. LV mass index (indexed to height to the power of 2.7) and LV hypertrophy (defined as septal or posterior wall thickness  $>1.2$  cm) were assessed. Early diastolic tissue velocity (E prime) was used as a marker of diastolic dysfunction. An abnormal exercise echo was defined as the presence of scar (resting wall-motion abnormality that did not change with stress) or ischemia (new or worsening wall-motion abnormality).

### Statistical Analyses

Statistical analyses were performed using standard statistical software (SPSS Version 11.5, North Sydney, Australia). Results are expressed as mean  $\pm$  SD, median (interquartile range [IQR]), or frequencies (%) depending on the distribution of the data. Comparisons of means were made using unpaired  $t$  test, the Mann-Whitney test, or

Table 1. Assessment of physical activity levels in the preceding week<sup>a</sup>

Category	Core Questions
1	How many times have you walked continuously, for at least 10 min, for recreation, exercise, or to get from place to place?
2	How many times did you do household chores that made you breathe harder or puff and pant?
3	How many times did you do gardening or heavy work around the yard that made you breathe harder or puff and pant?
4	How many times did you do vigorous exercise that made you breathe harder or puff and pant (e.g., tennis, jogging, cycling)?

<sup>a</sup>Adapted from the Physical Activity Statewide Questionnaire (18). Categories 1, 2, and 3 are classed as moderate-intensity activity; category 4 is classed as vigorous activity.

Table 2. Baseline characteristics of glucose-intolerant renal transplant recipients with and without MS

Variable	With MS (n = 45)	Without MS (n = 26)	P
<b>Demographics</b>			
age (yr)	55.3 ± 9.8	52.6 ± 9.5	0.27
male gender (%)	25 (56)	15 (58)	0.86
white race (%)	39 (87)	18 (69)	0.08
transplant duration (yr)	6.8 (3.1 to 13.2)	5.4 (2.9 to 10.3)	0.63
BMI (kg/m <sup>2</sup> )	29.0 ± 4.4	26.9 ± 6.1	0.09
eGFR (ml/min)	66.9 ± 21.4	66.7 ± 16.1	0.97
<b>Primary cause of renal failure (%)</b>			
glomerulonephritis	16 (36)	7 (27)	0.45
adult polycystic kidney disease	8 (18)	6 (23)	0.59
miscellaneous	11 (24)	5 (19)	0.61
diabetic nephropathy	3 (1)	2 (1)	0.87
uncertain cause	7 (16)	6 (23)	0.43
<b>Cardiovascular risk factors (%)</b>			
previous cardiac event	7 (16)	5 (19)	0.69
hypertension	42 (93)	22 (85)	0.24
dyslipidemia	34 (76)	17 (65)	0.36
diabetes	25 (56)	12 (46)	0.45
smoking (current or former)	16 (36)	11 (42)	0.57
<b>MS risk factors</b>			
hypertension (%)	44 (98)	23 (89)	0.1
central obesity (%)	36 (80)	6 (23)	<0.001
hypertriglyceridemia (%)	34 (76)	4 (15)	<0.001
reduced HDL cholesterol (%)	8 (18)	0 (0)	0.02
FBG ≥6.1 mmol/L or diabetes	37 (82)	13 (50)	0.004
<b>Immunosuppression (%)</b>			
prednisolone	36 (80)	19 (73)	0.50
cyclosporine	31 (69)	17 (65)	0.76
tacrolimus	9 (20)	5 (19)	0.94
mycophenolate mofetil	21 (47)	15 (58)	0.37
azathioprine	13 (29)	9 (35)	0.62
<b>Physical activity (%)</b>			
active	19 (47)	18 (70)	0.03
activity target	22 (48)	20 (76)	0.02
<b>CF and imaging parameters</b>			
peak VO <sub>2</sub> (ml/kg per min)	16.9 ± 5.9	22.4 ± 7.5	0.001
left atrial volume (cm <sup>3</sup> )	65 ± 16	61 ± 21	0.42
LV end systolic volume (ml)	38 ± 22	40 ± 21	0.77
LV end diastolic volume (ml)	86 ± 34	88 ± 44	0.86
ejection fraction (%)	59 ± 9	56 ± 10	0.15
LV mass index (g/m <sup>2.7</sup> )	64 ± 22	53 ± 17	0.04
E prime (cm/s)	5.8 ± 1.4	6.1 ± 1.8	0.07
LV hypertrophy (%)	37 (82)	21 (81)	0.88
myocardial ischemia (%)	10 (22)	4 (15)	0.49
carotid IMT (mm)	0.63 ± 0.13	0.60 ± 0.09	0.31

Data are mean ± SD, median (IQR), or frequencies (%). BMI, body mass index; eGFR, estimated GFR; E prime, early diastolic tissue velocity; FBG, fasting blood glucose; IMT, intima-media thickness; LV, left ventricular; MS, metabolic syndrome; VO<sub>2</sub>, oxygen consumption.

Pearson  $\chi^2$  test.  $P < 0.05$  was considered statistically significant. Univariate and multivariate linear regression analyses were performed to determine, first, which demographic, clinical, and imaging variables

were associated with peak VO<sub>2</sub> and, second, the incremental value of imaging parameters over demographic and clinical variables in predicting peak VO<sub>2</sub>.

All variables first were evaluated by univariate linear regression analysis to identify those that were associated with peak  $\text{VO}_2$ . The following variables were assessed: (1) demographic (age, gender, race, height, weight, and BMI), (2) clinical (duration of dialysis before transplantation and duration of current transplant, cardiovascular risk factors [previous cardiac event, hypertension, dyslipidemia, diabetes, smoking status, MS, and number of MS risk factors], medications [immunosuppression agents, statins, antihypertensive agents, and hypoglycemic agents], biochemical parameters [eGFR, glucose, HbA1c%, hemoglobin, and all lipid parameters], and activity target and activity status), and (3) imaging (echocardiographic parameters [left atrial volume, LV volumes, LV ejection fraction, LV hypertrophy, E prime, and myocardial ischemia] and carotid IMT). Any variables with  $P < 0.1$  on univariate analysis, which were not collinearly associated, then were entered into a multivariate regression analysis, and the final multivariate model was obtained using a stepwise backward elimination procedure of variables with  $P > 0.05$ . Standard regression diagnostics were performed for all models.  $R^2$  values are reported only for significant results.

To assess the incremental value of imaging parameters over demographic and clinical variables, we performed a stepwise procedure in three steps. In the first step, a multivariate model of significant demographic variables was developed (model 1). In the second step, a multivariate model of significant clinical variables was developed and added to model 1 to give a multivariate model of demographic and clinical variables (model 2). In the third step, imaging parameters with  $P < 0.1$  on univariate analysis were added to model 2. By using a stepwise backward elimination procedure of imaging variables with  $P > 0.05$ , a final model of independent demographic, clinical, and imaging variables was obtained (model 3). A significant improvement in model prediction between one model and the next was assessed from the difference in  $R^2$  values and the  $P$  value associated with the F-statistic change.  $P < 0.05$  was taken to be indicative of a significant increment between consecutive models.

## Results

### Clinical Characteristics

Seventy-one glucose-intolerant patients were recruited to the study (study cohort). Mean age of glucose-intolerant RTR was  $54.4 \pm 9.7$  yr, and 55% were male. Median transplant duration was 5.7 yr (IQR 3.0 to 12.8 yr). Twenty-five RTR with normal glucose tolerance acted as a control cohort. Mean age of control subjects was  $53.2 \pm 11.2$  yr ( $P = 0.64$ ), 12 (47%) patients were male ( $P = 0.48$ ), and median transplant duration was 6.4 yr (IQR 1.3 to 11.6 yr;  $P = 0.56$ ). Individuals with abnormal glucose tolerance were heavier than those with normal glucose tolerance ( $28.3 \pm 5.1$  versus  $25.6 \pm 3.7$  kg/m<sup>2</sup>;  $P = 0.04$ ).

### Physical Activity, Exercise Testing, CF, and Myocardial Ischemia

In the study cohort, 33 (47%) RTR achieved activity target. Mean duration of treadmill exercise was  $6.1 \pm 2.9$  min. Systolic and diastolic BP increased with exercise ( $135 \pm 14$  to  $169 \pm 24$  mmHg [ $P < 0.001$ ] and  $81 \pm 9$  to  $90 \pm 8$  mmHg [ $P < 0.001$ ]; respectively). Forty-three (61%) RTR achieved target heart rate (>85% of age-predicted maximum), and 85% of RTR achieved a respiratory quotient >1. Reasons for terminating the test were fatigue ( $n = 57$ ), dyspnea ( $n = 3$ ), leg discomfort ( $n = 6$ ), atrial fibrillation ( $n = 3$ ), and poor coordination ( $n = 2$ ). Peak  $\text{VO}_2$  in the study cohort was  $18.8 \pm 7.1$  ml/kg per min and was lower




Figure 1. Percentage of patients within each self-perceived activity category who achieve recommended targets of moderate physical activity.

than both the peak  $\text{VO}_2$  in the control cohort ( $23.3 \pm 7.9$  ml/kg per min;  $P = 0.01$ ) and the predicted  $\text{VO}_2$  ( $28.9 \pm 6.3$  ml/kg per min;  $P < 0.001$ ). Only 7 (10%) RTR achieved predicted  $\text{VO}_2$ . Fourteen (20%) glucose-intolerant RTR had silent myocardial ischemia compared with four (16%) normal glucose tolerance control subjects ( $P = 0.68$ ).

### MS

Forty-five (63%) glucose-intolerant RTR had MS compared with five (20%) with normal glucose tolerance ( $P < 0.001$ ). Table 2 shows the baseline characteristics of glucose-intolerant patients with and without MS. Patients with MS had lower HDL cholesterol, higher waist circumference, triglycerides, and fasting blood glucose levels and were more likely to have diabetes. The relationship between MS and (1) physical activity, (2) CF, and (3) imaging variables in the study cohort was explored further.

**MS and Physical Activity.** In patients with MS, 19 (42%) perceived themselves to be active (very active  $n = 2$ ; active  $n = 17$ ) and the remainder (58%) considered themselves inactive (not very active  $n = 19$ ; not at all active  $n = 7$ ). In patients without MS, 18 (70%) perceived themselves to be active (very active  $n = 4$ ; active  $n = 14$ ) and the remaining 30% considered themselves not very active. Only 48% of patients with MS achieved the activity target compared with 76% without MS ( $P = 0.02$ ). However, in both groups, there was a significant correlation between patients' self-perceived activity status and




Figure 2. Relationship between number of metabolic syndrome (MS) risk factors and mean peak oxygen consumption ( $\text{VO}_2$ ).

the percentage achieving activity target (Figure 1). On treadmill testing, patients with MS exercised for less time ( $5.5 \pm 2.3$  min versus  $7.2 \pm 3.6$  min;  $P = 0.01$ ).

**MS and CF.** Patients with MS had reduced peak  $\text{VO}_2$  compared with those without MS ( $16.9 \pm 5.9$  versus  $22.4 \pm 7.5$  ml/kg per min;  $P = 0.001$ ). As the number of MS risk factors increased from one to four or more, mean peak  $\text{VO}_2$  decreased ( $P = 0.002$ ; Figure 2).

**MS and Imaging Parameters.** LV mass index was increased in RTR with MS ( $64 \pm 22$  versus  $53 \pm 17$  g/m<sup>2.7</sup>;  $P = 0.04$ ), but there were no significant differences in other resting two-dimensional echo parameters. MS was not associated with myocardial ischemia or abnormal IMT (Table 2).

#### Predictors of Peak $\text{VO}_2$

The variables that were associated with peak  $\text{VO}_2$  on univariate and multivariate analyses are shown in Table 3. No MS risk factors other than central obesity were associated with peak  $\text{VO}_2$ . Of note, eGFR did not independently predict CF. In the final multivariate model, peak  $\text{VO}_2$  was positively correlated with male gender, height, and activity status and inversely correlated with the number of MS risk factors and carotid IMT (Table 3). The adjusted  $R^2$  for this model was 0.66.

#### Incremental Value of Imaging Variables

The incremental value of imaging variables over demographic and clinical variables in determining CF is shown in Table 4 and Figure 3. In a multivariate model of significant demographic variables (gender and age, adjusted  $R^2 = 0.42$ ), addition of independent clinical variables (previous cardiac event, activity status, and number of MS risk factors) improved

the predictive power of the model (adjusted  $R^2 = 0.63$ ,  $P < 0.001$ ). The power of the model was improved further by addition of imaging variables (myocardial ischemia, LV end systolic volume, LV end diastolic volume, LV mass index, E prime, and carotid IMT), although only carotid IMT remained in the final model (adjusted  $R^2 = 0.65$ ,  $P = 0.04$ ), accounting for 13% of the variability in peak  $\text{VO}_2$  in this group.

## Discussion

### Principal Findings

This study demonstrates that after adjustment for gender and height, the principal correlates of reduced CF in glucose-intolerant RTR are physical inactivity, an adverse cardiovascular risk factor profile as defined by the number of MS risk factors, and atherosclerotic burden. Furthermore, the incremental value of atherosclerotic burden over clinical variables suggests that noninvasive cardiovascular imaging may supplement clinical information in the investigation of CF in this high-risk patient group.

### Physical Activity and CF in Glucose-Intolerant RTR

In this study, physical activity levels were impaired in glucose-intolerant RTR, with <50% of patients achieving currently recommended targets of physical activity. CF also was reduced, with only 10% of patients achieving predicted levels of peak  $\text{VO}_2$  during exercise testing. Regular physical activity has been shown to improve CF and reduce the incidence of cardiovascular events, independent of any beneficial effects on cardiovascular risk factors in the general population (24). Only two studies have studied physical activity levels in RTR (25,26). Gallagher-Lepak *et al.* (25)

Table 3. Variables associated with peak  $\text{VO}_2$  on univariate and multivariate linear regression analyses in glucose-intolerant renal transplant recipients ( $n = 71$ )

Variable	Univariate Analysis <sup>a</sup>		Multivariate Analysis	
	$R^2$	$P$	$R^2$	$P$
Gender	0.27	<0.001	0.04	0.003
Age (yr)	0.09	0.005	—	—
Height (m)	0.29	<0.001	0.30	0.01
Previous cardiac event	0.08	0.01	—	—
Hemoglobin (g/dl)	0.10	0.006	—	—
Physical activity status	0.15	0.002	0.17	0.001
Activity target	0.11	0.005	—	—
MS	0.14	0.001	—	—
No. of MS risk factors	0.10	0.003	0.11	0.001
Myocardial ischemia	0.05	0.052	0.01	0.06
LV end systolic volume (ml)	0.08	0.02	—	—
LV end diastolic volume (ml)	0.11	0.004	—	—
LV mass index (g/m <sup>2.7</sup> )	0.09	0.01	—	—
E prime (cm/s)	0.15	0.001	—	—
Carotid IMT (mm)	0.12	0.002	0.06	0.001

<sup>a</sup>On univariate analysis, peak  $\text{VO}_2$  was positively correlated with male gender, height, hemoglobin, physical activity status, and activity target and inversely correlated with age, previous cardiac event, MS and number of MS risk factors, myocardial ischemia, LV volumes, LV mass index, E prime, and carotid IMT.

Table 4. Incremental value of cardiovascular imaging variables over demographic and clinical variables in predicting peak VO<sub>2</sub> in glucose-intolerant renal transplant recipients (*n* = 71)

	Univariate Analysis		Multivariate Analysis		Model R <sup>2</sup>
	R <sup>2</sup>	P	R <sup>2</sup>	P	
Model 1					0.42
gender	0.27	<0.001	0.36	<0.001	
age (yr)	0.09	0.005	0.07	<0.001	
Model 2					0.63
gender	0.27	<0.001	0.28	<0.001	
age (yr)	0.09	0.005	0.10	<0.001	
previous cardiac event	0.08	0.01	0.03	0.03	
activity status	0.15	0.002	0.17	0.002	
no. of MS risk factors	0.10	0.003	0.08	<0.001	
Model 3					0.65
gender	0.27	<0.001	0.28	<0.001	
age (yr)	0.09	0.005	0.02	0.04	
previous cardiac event	0.08	0.01	0.03	0.07	
activity status	0.15	0.002	0.17	<0.001	
no. of MS risk factors					
myocardial ischemia	0.05	0.052	—	—	
LV end systolic volume (ml)	0.08	0.02	—	—	
LV end diastolic volume (ml)	0.11	0.004	—	—	
LV mass index (g/m <sup>2.7</sup> )	0.09	0.01	—	—	
E prime (cm/s)	0.15	0.001	—	—	
Carotid IMT (mm)	0.12	0.002	0.13	0.04	




Figure 3. Incremental value of clinical and imaging variables in predicting peak VO<sub>2</sub>. Left bar, model 1 (age and gender); middle bar, model 2 (age, gender, previous cardiac event, activity status, and number of MS risk factors); right bar, model 3 (age, gender, previous cardiac event, activity status, number of MS risk factors, and intima-media thickness).

monitored self-reported physical activity levels in nine patients before transplantation and at 6 and 16 wk after transplantation and observed a significant increase in physical activity during the 16-wk follow-up. In another study, the impact of transplantation on physical activity in both the short and the long term was evaluated in 32 patients who were assessed immediately before transplantation and then

at 3, 6, 12, and 60 mo after transplantation (26). The results identified that RTR had a 30% increase in physical activity levels by 1 yr after transplant that was maintained at 5 yr. Although both studies identified an improvement in physical activity with renal transplantation, neither study assessed whether posttransplantation levels of physical activity were comparable with recommended levels.

Data on CF using peak VO<sub>2</sub> assessment in RTR are similarly limited and pertain mainly to the benefits of regular physical activity on CF (5,27). In a study of 167 RTR who were randomly assigned at 1 mo after transplantation into an exercise intervention group and a usual care group and tested at baseline, 6 mo, and 12 mo, there was a statistically significant improvement in CF in RTR in the exercise intervention group compared with baseline (5). The long-term benefits of regular exercise with respect to CF and cardiovascular outcomes in RTR remain uncertain.

#### Impact of MS on Physical Activity and CF

In the nontransplant population, metabolic parameters have been identified as important determinants of CF in a number of studies (6–8). Furthermore, MS prevalence is higher in individuals who have reduced CF and are physically inactive (28–30). Recent evidence also suggests that reduced CF is itself an independent predictor of incident MS (31,32). Thus, the interrelation between MS and CF is well established in the general population.

In the renal transplant population, the relationship among

MS, physical activity, and CF has not been explored previously. In this study, glucose-intolerant RTR with MS were physically inactive with reduced CF compared with those without MS. In addition, the number of MS risk factors was an independent determinant of CF. Although this association was demonstrated recently in nontransplant individuals (33), to the best of our knowledge, this is the first study to identify a dose–response association between the number of metabolic components and CF in RTR. Painter *et al.* (34) reported on the relationship between coronary heart disease (CHD) risk using the Framingham risk equation and CF in RTR. They examined the effects of exercise training on CF and CHD risk in 96 RTR who were randomly assigned to an exercise training group and a usual care group at 1 mo after transplantation. After 1 yr, physical activity levels and CF improved in patients in the exercise training group. However, there was no change in 10-yr CHD risk by Framingham, either over time or between the groups over time. Moreover, there was a significant negative correlation between CF and CHD risk ( $r = -0.406$ ,  $P < 0.001$ ).

In this study, several other markers of CVD, including a previous cardiac event, and echocardiographic parameters such as increased LV mass, increased LV volumes, and myocardial ischemia, all correlated with reduced CF on univariate analysis. Furthermore, abnormal IMT added incremental value to clinical variables in determining CF. IMT is associated with atherogenic risk factors and cardiovascular events in RTR (35,36) and is a useful marker of subclinical atherosclerosis even in the absence of clinical evidence of CVD (37,38). This finding provided supplementary evidence of a strong link between cardiovascular risk and reduced CF in glucose-intolerant RTR.

### Limitations

Although this study has identified an important relationship among CF, physical activity, and MS in RTR, there were a number of limitations. These included the small sample size and the exclusion of individuals with normal glucose tolerance in the statistical analyses. By only assessing glucose-intolerant RTR, we were unable to evaluate the impact, if any, of glucose intolerance on CF, which casts doubt on the generalizability of these findings to all RTR. It should be noted, however, that because mean peak  $\text{VO}_2$  was significantly higher in an age- and gender-matched cohort of normal glucose-tolerant transplant recipients, it is possible that disorders of glucose homeostasis indeed may be important in contributing to reduced CF in RTR. Further studies should include glucose intolerance as a categorical variable in any statistical analyses to explore this association further.

Although data were collected on activity status, we did not determine the specific reasons for inactivity in patients who perceived themselves as inactive. This supplementary information may have proved useful in further evaluating the limitations to CF, particularly because deconditioning and patient motivation are difficult to quantify accurately. Furthermore, data on physical activity would have been useful in individuals with normal glucose tolerance.

A further limitation was that baseline spirometry was not performed before exercise testing. This information could have helped to exclude significant ventilatory limitation that contributed to reduced CF in RTR, rather than relying on estimated ventilatory limitation. However, the significant positive correlation between estimated ventilatory limitation and peak  $\text{VO}_2$  in the patient group ( $r = 0.6$ ,  $P < 0.001$ ), along with the small proportion of patients observed to terminate exercise because of dyspnea, suggest that respiratory dysfunction was unlikely to be a significant factor limiting CF in the group as a whole. Finally, the observational nature of this study makes it impossible to determine whether markers of cardiovascular risk, such as number of MS risk factors and subclinical atherosclerosis are direct causes of reduced CF or are consequences or associated phenomena. Further studies are required to evaluate this association further.

### Conclusion

Despite these limitations, the findings from this study are important. Physical inactivity, MS, and reduced CF are major risk factors for CVD in the general population (1,39–41). Similar factors may operate in the pathogenesis of CVD in RTR. The cardiovascular benefits of regular exercise and optimal CF are well established in the general population. However, whether similar benefits are afforded to RTR is uncertain. Prospective studies are needed to address whether physical activity and modification of cardiovascular risk factors translate into improved CF and long-term cardiovascular outcomes in RTR and the precise impact of disorders of glucose homeostasis on CF in this patient group. Furthermore, the prognostic significance of silent myocardial ischemia needs to be clarified before increased physical activity is prescribed routinely in all RTR.

### Acknowledgments

K.A. was supported by a Clinical Centre of Research Excellence Award from the National Health and Medical Research Council of Australia and a Cardiovascular Lipid Research Grant awarded by Pfizer.

We gratefully acknowledge the help with data collection provided by Rachael Pidcock and Linda Orazio, the advice provided by Neil Smart (exercise physiologist), and Elaine Beller (statistician) and the assistance of the staff and patients in the Renal Unit at the Princess Alexandra Hospital, Brisbane.

### References

1. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE: Exercise capacity and mortality among men referred for exercise testing. *N Engl J Med* 346: 793–801, 2002
2. Johansen KL: Physical functioning and exercise capacity in patients on dialysis. *Adv Ren Replace Ther* 6: 141–148, 1999
3. Moore GE, Parsons DB, Stray-Gundersen J, Painter PL, Brinker KR, Mitchell JH: Uremic myopathy limits aerobic capacity in hemodialysis patients. *Am J Kidney Dis* 22: 277–287, 1993
4. Painter P, Hanson P, Messer-Rehak D, Zimmerman SW, Glass NR: Exercise tolerance changes following renal transplantation. *Am J Kidney Dis* 10: 452–456, 1987

5. Painter PL, Hector L, Ray K, Lynes L, Dibble S, Paul SM, Tomlanovich SL, Ascher NL: A randomized trial of exercise training after renal transplantation. *Transplantation* 74: 42–48, 2002
6. Fang ZY, Sharman J, Prins JB, Marwick TH: Determinants of exercise capacity in patients with type 2 diabetes. *Diabetes Care* 28: 1643–1648, 2005
7. Bertoli A, Di Daniele N, Ceccobelli M, Ficara A, Girasoli C, De Lorenzo A: Lipid profile BMI, body fat distribution, and aerobic fitness in men with metabolic syndrome. *Acta Diabetol* 40[Suppl 1]: S130–S133, 2003
8. Peterson MJ, Pieper CF, Morey MC: Accuracy of VO<sub>2</sub>(max) prediction equations in older adults. *Med Sci Sports Exerc* 35: 145–149, 2003
9. Robbins AS, Chao SY, Fonseca VP, Snedecor MR, Knapik JJ: Predictors of low physical fitness in a cohort of active-duty US Air Force members. *Am J Prev Med* 20: 90–96, 2001
10. Armstrong KA, Prins J, Beller EM, Campbell SB, Hawley CM, Johnson DW, Isbel NM: Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? *Clin J Am Soc Nephrol* 1: 100–108, 2006
11. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant* 3: 178–185, 2003
12. Aakhus S, Dahl K, Wideroe TE: Cardiovascular morbidity and risk factors in renal transplant patients. *Nephrol Dial Transplant* 14: 648–654, 1999
13. Painter PL, Topp KS, Krasnoff JB, Adey D, Strasner A, Tomlanovich S, Stock P: Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. *Kidney Int* 63: 2309–2316, 2003
14. Sietsema KE, Hiatt WR, Esler A, Adler S, Amato A, Brass EP: Clinical and demographic predictors of exercise capacity in end-stage renal disease. *Am J Kidney Dis* 39: 76–85, 2002
15. *Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus*, Geneva, World Health Organization, 1999
16. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR: Predicting glomerular filtration rate after kidney transplantation. *Transplantation* 59: 1683–1689, 1995
17. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 106: 3143–3421, 2002
18. Armstrong T, Bauman A, Davies J: *Physical Activity Patterns of Australian Adults*, Canberra, Australian Institute of Health and Welfare, 2000, pp 1–79
19. *National Physical Activity Guidelines for Australians*, Department of Health and Ageing, Canberra, 2005
20. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. National Institutes of Health. *Obes Res* 6[Suppl 2]: 51S–209S, 1998
21. Bruce RA, Kusumi F, Hosmer D: Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. *Am Heart J* 85: 546–562, 1973
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 16: 5–40, 1993
23. Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick TH: Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? *Am J Med* 110: 198–204, 2001
24. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW: Physical fitness and all-cause mortality. A prospective study of healthy men and women. *JAMA* 262: 2395–2401, 1989
25. Gallagher-Lepak S: Functional capacity and activity level before and after renal transplantation. *ANNA J* 18: 378–382, 1991
26. Nielens H, Lejeune TM, Lalaoui A, Squifflet JP, Pirson Y, Goffin E: Increase of physical activity level after successful renal transplantation: A 5 year follow-up study. *Nephrol Dial Transplant* 16: 134–140, 2001
27. Violan MA, Pomes T, Maldonado S, Roura G, De la Fuente I, Verdaguer T, Lloret R, Torregrosa JV, Campistol JM: Exercise capacity in hemodialysis and renal transplant patients. *Transplant Proc* 34: 417–418, 2002
28. Farrell SW, Cheng YJ, Blair SN: Prevalence of the metabolic syndrome across cardiorespiratory fitness levels in women. *Obes Res* 12: 824–830, 2004
29. Jurca R, LaMonte MJ, Church TS, Earnest CP, Fitzgerald SJ, Barlow CE, Jordan AN, Kampert JB, Blair SN: Associations of muscle strength and fitness with metabolic syndrome in men. *Med Sci Sports Exerc* 36: 1301–1307, 2004
30. Lakka TA, Laaksonen DE, Lakka HM, Mannikko N, Niskanen LK, Rauramaa R, Salonen JT: Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. *Med Sci Sports Exerc* 35: 1279–1286, 2003
31. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka TA: Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. *Diabetes Care* 25: 1612–1618, 2002
32. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN: Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: A prospective study of men and women. *Circulation* 112: 505–512, 2005
33. Wong CY, O'Moore-Sullivan T, Fang ZY, Haluska B, Leano R, Marwick TH: Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. *Am J Cardiol* 96: 1686–1691, 2005
34. Painter PL, Hector L, Ray K, Lynes L, Paul SM, Dodd M, Tomlanovich SL, Ascher NL: Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. *Am J Kidney Dis* 42: 362–369, 2003
35. Barbagallo CM, Pinto A, Gallo S, Parrinello G, Caputo F, Sparacino V, Cefalu AB, Novo S, Licata G, Notarbartolo A, Aversa MR: Carotid atherosclerosis in renal transplant recipients: Relationships with cardiovascular risk factors and plasma lipoproteins. *Transplantation* 67: 366–371, 1999
36. Massy ZA, Mamzer-Bruneel MF, Chevalier A, Millet P, Helenon O, Chadeaux-Vekemans B, Legendre C, Bader C, Druke T, Lacour B, Kreis H: Carotid atherosclerosis in renal transplant recipients. *Nephrol Dial Transplant* 13: 1792–1798, 1998
37. Cofan F, Gilibert R, Nunez I, Zambon D, Ros E, Casals E,



- Cofan M, Muray S, Campistol JM, Bru C, Oppenheimer F: Influence of renal posttransplantation dyslipidemia on the degree and severity of carotid and femoral atherosclerosis evaluated by B-mode ultrasound. *Transplant Proc* 34: 412–414, 2002
38. Suwelack B, Witta J, Hausberg M, Muller S, Rahn KH, Barenbrock M: Studies on structural changes of the carotid arteries and the heart in asymptomatic renal transplant recipients. *Nephrol Dial Transplant* 14: 160–165, 1999
39. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 52: 1210–1214, 2003
40. Laukkanen JA, Lakka TA, Rauramaa R, Kuhanen R, Venalainen JM, Salonen R, Salonen JT: Cardiovascular fitness as a predictor of mortality in men. *Arch Intern Med* 161: 825–831, 2001
41. Lynch J, Helmrach SP, Lakka TA, Kaplan GA, Cohen RD, Salonen R, Salonen JT: Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. *Arch Intern Med* 156: 1307–1314, 1996